PLSE vs ANAB

Analysts rate Pulse Biosciences, Inc.

(PLSE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AnaptysBio, Inc.

(ANAB) delivered a total return of +304. 3%, compared to +17. 0% for Pulse Biosciences, Inc. (PLSE). Over 10 years, the gap is even starker: ANAB returned +511. 9% versus PLSE's +357. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AnaptysBio, Inc.

(ANAB) is the lower-risk stock at 0. 97β versus Pulse Biosciences, Inc. 's 1. 91β — meaning PLSE is approximately 97% more volatile than ANAB relative to the S&P 500. On balance sheet safety, Pulse Biosciences, Inc. (PLSE) carries a lower debt/equity ratio of 9% versus 38% for AnaptysBio, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: AnaptysBio, Inc.

grew EPS 91. 0% year-over-year, compared to -17. 4% for Pulse Biosciences, Inc.. Over a 3-year CAGR, ANAB leads at 183. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AnaptysBio, Inc.

(ANAB) is the more profitable company, earning -5. 6% net margin versus -207. 9% for Pulse Biosciences, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANAB leads at 20. 4% versus -219. 8% for PLSE. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AnaptysBio, Inc.

(ANAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), +511. 9% 10Y return). Pulse Biosciences, Inc. (PLSE) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ANAB: +511. 9%, PLSE: +357. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLSE is a small-cap quality compounder stock; ANAB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.